Experimental Hematology
Volume 38, Issue 8 , Pages 641-652 , August 2010

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia

  • Nuria Barbarroja

      Affiliations

    • Laboratorio de Investigaciones Biomédicas, Fundación IMABIS, Hospital Universitario Virgen de la Victoria, Málaga, Spain
    • Corresponding Author InformationOffprint requests to: Nuria Barbarroja Puerto, Ph.D., Laboratorio de Investigaciones Biomédicas, Hospital Universitario Virgen de la Victoria, Avda. Campus de Teatinos s/n, E-29010 Málaga, Spain
    • ,
  • Luis-Arístides Torres

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
    • ,
  • Antonio Rodriguez-Ariza

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
    • ,
  • Araceli Valverde-Estepa

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
    • ,
  • Laura Maria Lopez-Sanchez

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
    • ,
  • Patricia Ruiz-Limon

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
    • ,
  • Carlos Perez-Sanchez

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
    • ,
  • Rosario Maria Carretero

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain
    • ,
  • Francisco Velasco

      Affiliations

    • Servicio de Hematología, Hospital Universitario Reina Sofía, Córdoba, Spain
    • ,
  • Chary López-Pedrera

      Affiliations

    • Unidad de Investigación, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain

Received 12 January 2010 ,Revised 26 March 2010 ,Accepted 26 March 2010.

References 

  1. Kuzu I, Beksac M, Arat M, Celebi H, Elhan AH, Erekul S. Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymph. 2004;45:1185–1190
  2. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–2245
  3. Aguayo A, Kantarjian HM, Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002;95:1923–1930
  4. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;3:9–22
  5. Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302–1310
  6. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106:511–521
  7. Zhang H, Li Y, Li H, et al. Inhibition of both the autocrine and the paracrine growth of human leukemia with a fully human anti-body directed against vascular endothelial growth factor receptor 2. Leuk Lymph. 2004;45:1887–1897
  8. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–1875
  9. Santos SC, Dias S. Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood. 2004;103:3883–3889
  10. List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol. 2004;32:526–535
  11. Weber-Nordt RM, Mertelsmann R, Finke J. The JAK-STAT pathway: signal transduction involved in proliferation, differentiation and transformation. Leuk Lymph. 1998;28:459–467
  12. Grandage VL, Gale RE, Linch DC, Kchwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005;19:586–594
  13. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49–139
  14. Kainz B, Fonatsch C, Schwarzinger I, Sperr WR, Jäger U, Gaiger A. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia. Haematologica. 2005;90:695–696
  15. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752–1759
  16. Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood. 2002;99:4326–4335
  17. Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66
  18. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105:986–993
  19. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with a potent activity in vitro and in vivo. Blood. 2003;101:3597–3605
  20. Roboz GJ, Giles FJ, List AF, et al. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia. 2006;20:952–957
  21. Barbarroja N, Torres LA, Luque MJ, et al. Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia. Exp Hematol. 2009;37:679–691
  22. Traxler P, Allegrini PR, Brandt R, et al. AEE788: a dual family epidermal growth factor receptor/erbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931–4941
  23. Okamoto K, Neureiter D, Alinger B, et al. The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice. Int J Oncol. 2008;33:733–742
  24. Baselga J, Rojo F, Dumez H, et al. Phase I study of AEE788, a novel multitargeted inhibitor of erbB and VEGF receptor family tyrosine kinases: a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen. Proc Am Soc Clin Oncol. 2005;23:3028a
  25. Martinelli E, Takimoto C, van Oosterom A, et al. AEE788, a novel multitargeted inhibitor of erbB and VEGF receptor family tyrosine kinases; preliminary phase I results. Proc Am Soc Clin Oncol. 2005;23:3039a
  26. Reardon D, Cloughesy T, Conrad C, et al. A phase I study of AEE788, a novel multitargeted inhibitor of erbB and VEGF receptor family tyrosine kinases, in recurrent GBM patients. Proc Am Soc Clin Oncol. 2005;23:3063a
  27. Xiong HQ, Takimoto C, Rojo F, et al. A phase I study of AEE788, a multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases to determine safety, PK and PD in patients (pts) with advanced colorectal cancer (CRC) and liver metastases. J Clin Oncol. 2007 ASCO Annual Meeting Proc. 2007;25:4065;(Abstract)
  28. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637–2644
  29. Barbarroja N, Arístides-Torres L, Hernandez V, et al. Coordinated deregulation of cellular receptors, proangiogenic factors and intracellular pathways in acute myeloid leukaemia. Leuk Lymph. 2007;48:1187–1199
  30. Blazquez C, Cook N, Micklen K, Harris AL, Gatter KC, Pezzella F. Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Res. 2006;16:93–98
  31. Park YW, Younes MN, Jasser SA, et al. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res. 2005;11:1963–1973
  32. Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. 2005;65:3716–3725
  33. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappa B is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301–2307
  34. Hoffmann S, Burchert A, Wunderlich A, et al. Differential effects of cetuximab and AEE788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines. Endocrine. 2007;31:105–113
  35. Kuwai T, Nakamura T, Sasaki T, et al. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis. 2008;25:477–489
  36. O'Farrell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res. 2003;9:5465–5476
  37. Bellamy W, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplasic syndromes. Blood. 2001;97:1427–1434
  38. Weidenaar AC, de Jonge HJ, Fidler V, et al. Addition of PTK787/ZK222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death. Anticancer Drugs. 2008;19:45–54
  39. Oveland E, Gjertsen BT, Wergeland L, Selheim F, Fladmark KE, Hovland R. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leuk Res. 2009;33:276–287
  40. Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol. 2001;40:231–252
  41. Huamani J, Willey C, Thotala D, et al. Differential efficacy of combined therapy with radiation and AEE788 in high and low EGFR-expressing androgen-independent prostate tumor models. Int J Radiation Oncol Biol Physics. 2008;71:237–246
  42. Choudhary C, Brandts C, Schwable J, et al. Activation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood. 2007;110:370–374
  43. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669–3676
  44. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108:3262–3270
  45. Stone RM, De Angelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54–60
  46. Knapper S, Mills KI, Gilkes AF, et al. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood. 2006;108:3494–3503
  47. Levis M, Stine A, Pham R, et al. Pharmacokinetic and pharmacodynamic studies of lestaurtinib (CEP-701) and PKC-412: cytotoxicity is often dependent on non-FLT3-mediated effects (abstract). Blood. 2005;106:Abstract 2463
  48. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669–3676
  49. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54–60

PII: S0301-472X(10)00132-3

doi: 10.1016/j.exphem.2010.03.017

Experimental Hematology
Volume 38, Issue 8 , Pages 641-652 , August 2010

Article Tools

* Image Usage & Resolution